Vinati Organics Limited (524200) Earnings Call Transcript & Summary

November 19, 2025

BSE IN Materials Chemicals earnings 7 min

Earnings Call Speaker Segments

Nigel D'Souza

attendee
#1

From [ Vini, ] let's go across to Vinati Organics. That's the next management on the show. The company reported actually a mixed set of numbers, lower input costs led to strong margin expansion. To discuss the past quarter and more importantly, the way ahead, we have with us Vinati Saraf Mutreja, the Managing Director at Vinati Organics.

Nigel D'Souza

attendee
#2

Vinati, always good to have you on the show. Thanks a lot for joining in today. Well, let's focus on the way ahead. And you had mentioned in the past, over the next 3 years or so, you're looking at a 20% CAGR growth in terms of revenue with margins in the vicinity of 26%, 27% or thereabouts. But let's talk about this year first. How confident are you of that 15% revenue growth that you were talking about for FY '26? The first half of the year has been a mild growth out there. So that's why I want to understand for the year, what kind of revenue can you do? And also margins, first half of the year, you've done well out there. It's closer to around 30%, but still you're talking about 27%. So guidance on both these 2 parameters.

Vinati Mutreja

executive
#3

See, when I say revenue growth, I think I should correct myself and call it volume growth because revenue is a function of volume and price. And so while year-on-year and quarter-on-quarter, we are seeing volume growth of our products, especially coming from the new products, the additives business as well as from our subsidiary as well as ATBS, now we have started the new line, which just got commissioned a few weeks back. So given all of that, yes, we see volume growth. Of course, the prices of raw materials have fallen, freight prices have fallen, which has also led to a reduction in prices of my end product and, hence, you see a margin expansion as well. So it's actually been a very good set of first half or good Q2 and looking forward to Q3 and Q4 as well.

Nigel D'Souza

attendee
#4

Okay. So just to revise that, then for this year, if you could talk about volume growth, revenue growth and margin, just clear the air, what should the range be now?

Vinati Mutreja

executive
#5

Exactly. So volume growth remains 15%. Like I said, volume coming from our expansion, additional volume coming from the new ATBS line as well as the new product. Revenue growth could be a little less, maybe 10%, 12% because there is a price correction given -- and margins, I would still maintain 27% simply just to be conservative, and since we will be entering new markets as well.

Nigel D'Souza

attendee
#6

Okay. All right. Talking about expansion then, if I'm not mistaken, I think your Phase 1 of the ATBS capacity has been commercialized this month itself. You could correct me on that. What is the initial volume? So there I think the total capacity was around 10,000 tonnes. And the second capacity will come on stream in April. Are volumes fully booked?

Vinati Mutreja

executive
#7

That's fully booked. At least for Phase 1 is looking good. It has started, yes, in this month. And we are ramping up production since we do have an order backlog. And the Phase 2 will -- is set to get commissioned around April, May 2026. That's right.

Nigel D'Souza

attendee
#8

Okay. All right. So you're saying that demand is strong enough, right, with...

Vinati Mutreja

executive
#9

And it is a 10,000 tonne expansion, you're absolutely right. That does increase our capacity by 25%.

Nigel D'Souza

attendee
#10

By 25%. What will be the new capacity then?

Vinati Mutreja

executive
#11

40,000. Again, depends on which quality, but 40,000 tonnes, yes, per annum.

Nigel D'Souza

attendee
#12

All right. Let's talk about a couple of other products, MEHQ as well as Guaiacol. They have not contributed meaningfully to the revenues. I think they were to do, I think, INR 350 crores, INR 400 crores or thereabouts. What did they do in the past quarter, if you could help us out with that? And what is leading to this delay in terms of ramp-up?

Vinati Mutreja

executive
#13

Sure. So when I say INR 350 crores, INR 400 crores, that was the overall revenue projection from VOPL, our subsidiary, which includes at least 5 or 6 products, MEHQ and Guaiacol being one of them. The other products, which are yet to be commissioned is PTAP, there is 4-MAP. Anisole, we had just -- is also yet to be commissioned. So it was a combination of these products. Yes, there has been a delay in MEHQ, Guaiacol because we did go in with a new process and a new technology, and that is taking some time to stabilize. Having said that, we have got the quality right, our product samples are approved. In fact, our trial orders on a commercial basis also, we have supplied and they've approved. So next year is looking positive for these products.

Nigel D'Souza

attendee
#14

Okay. And on the antioxidants part, you are now producing the largest amount of antioxidants in India?

Vinati Mutreja

executive
#15

Absolutely. And we are running at 60% volume capacity utilization. We've also reached profitability in that business. So antioxidant is looking good, and we are able to compete with imports. And given our backward integration into butyl phenols and IV, we do have an advantage and the demand in India for these products is growing compared to other countries.

Nigel D'Souza

attendee
#16

All right. In the past, we have discussed about this Chinese threat with regard to antioxidants. And you said that maybe there could be some kind of protection as well, but something that you all were lobbying for. How are things looking as of now? Is -- are imports still a threat? Because that Chinese, the more they produce, you always get a little bit sketchy on that front. So what are the trends you're observing on antioxidants?

Vinati Mutreja

executive
#17

Well, the DGTR has recommended an antidumping duty on Chinese products as well as products from Singapore, but the Ministry of Finance is yet to revert. So we are waiting on that. When that comes, then that will be a quite big positive development, yes.

Nigel D'Souza

attendee
#18

All right. And as a percentage right now, are Chinese imports still coming in?

Vinati Mutreja

executive
#19

Yes, they're absolutely coming in. We are servicing probably about 40% of the domestic demand and imports are coming in from China, Singapore, Korea.

Nigel D'Souza

attendee
#20

Okay. All right. So if it comes in, then definitely it will be a positive because I think antioxidants as a percentage of your overall revenue is low teens. It's around 11%, 12%. Could you tell us how do you expect this to scale up? What is the percentage contribution from antioxidants to the total revenues? And...

Vinati Mutreja

executive
#21

Well, you're absolutely right. I'm surprised you're getting the numbers so correct.

Nigel D'Souza

attendee
#22

No, Vinati, I normally get it right. But correct me on those numbers with regard to how do you see things panning out?

Vinati Mutreja

executive
#23

No, no, you're right. AO is right now 11% to 12% of our revenue. And if things go as planned in the future, that could go up to 15%, 16%, again, because the other products will -- ATBS will also contribute to our revenue growth.

Nigel D'Souza

attendee
#24

Okay. All right. Got that, Vinati. Good conversation. And I think you've told us in the past that U.S. tariffs is not really hurting you all, right, as of now?

Vinati Mutreja

executive
#25

That is correct because my major export to the U.S. is ATBS and related products, which is under exemption.

Nigel D'Souza

attendee
#26

Okay. Vinati, you've given us a fair idea about business. How do you see things pan out? And as you've mentioned numerous times, 20% revenue growth is what you're looking at for the next 3 years on an annualized basis with margins closer to around that 26%, 27%. Wishing you a good day ahead, and we look forward to having a chat with you, Vinati, rather soon. Thanks for joining in.

Vinati Mutreja

executive
#27

Thank you. Bye.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Vinati Organics Limited transcript — plus 251,000+ transcripts from 12,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Vinati Organics Limited earnings transcripts and 251,000+ others is available through the EarningsCalls.dev REST API. Plans from $24.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.